

PRESCRIPTION AND ENROLLMENT FORM



Healthcare providers:

- Please submit completed enrollment form, copy of all insurance cards (front and back), and copy of patient's clinical chart notes to Acadia Connect®
- Have the parent/legal guardian read Section 8 and sign where indicated
- Fax the completed form to Acadia Connect at 1-888-385-2748
- If your office has not received a confirmation fax that your enrollment form has been received within one (1) business day after submission, please resubmit or call Acadia Connect at 1-844-737-2223, Monday to Friday, 8AM to 8PM ET

1 PATIENT AND PARENT/LEGAL GUARDIAN INFORMATION

PATIENT INFORMATION

Please select one: First Name:	□ Newly Prescribed Pc		ent Clinical Trial ID Last Name:			
Address:		City:	State:		ZIP Code:	
Date of Birth (MM/DE)/YYYY):	Gender:				
PARENT/LEGAL GUA	RDIAN INFORMATION					
First Name:		Last Name: _				
Relationship to Patier	nt:	Preferred La	nguage: 🗌 English	🗆 Spanish	□ Other	
Home Phone #:		Mol	oile Phone #:			
Work Phone #:		Pret	erred Phone #:	□ Home	□ Work	🗆 Mobile
Best Time to Call: Email Address:	3	on 🗌 Evening Car	We Leave a Message?	P 🗌 Yes	□ No	

2 INSURANCE INFORMATION No insurance Primary Medical Insurance Name:_____ _____ Group #: _____ Phone #: _____ Policy #:___ Policy Holder's Full Name: _____ Relationship to Patient: Date of Birth (MM/DD/YYYY): _____ _____ Rx Phone #: _____ Prescription Drug Insurance Name: _____ _____ Rx PCN #:_____ Rx BIN #:_____ Rx Group #: Secondary Medical Insurance Name: ____ Policy #:_____ _____ Group #: _____ Phone #: _____ Policy Holder's Full Name: _____ Date of Birth (MM/DD/YYYY): ______ Relationship to Patient: _____ _____ Rx Phone #: _____ Prescription Drug Insurance Name: ____ Rx Group #: _____ Rx PCN #: _____ _____ Rx BIN #: _____

3 ADDITIONAL CARE TEAM INFORMATION (eg, neurologist, physical therapist, school nurse, pediatrician, gastroenterologist)

By providing this information, I certify that I have permission from the following care team members to disclose their personally identifiable information to, and be contacted by, Acadia Pharmaceuticals Inc. (including its representatives and agents) for the purpose of supporting the patient's care and treatment on DAYBUETM (trofinetide).

CARE TEAM ROLE	NAME	EMAIL	PHONE



Patient's Name: _

PRESCRIPTION AND ENROLLMENT FORM



Date of Birth (MM/DD/YYYY): ___

4 PRESCRIBER INFORMATION			
Prescriber First Name:	Last Name:		_
Prescriber Specialty:	Practice Name:		_
Address:	City:	State: ZIP Code:	-
NPI #:	Medical Provider ID #:	DEA #:	_
Phone #:	Fax #:		
Office Contact:	Contact Phone #:	Contact Email:	-

5 CLINICAL INFORMATION Applicable ICD-10 Code: Has the Patient Had Genetic Testing? Yes No Date of Test:

	(methyl-CpG binding protein 2 [MECP2])	
Genetic Test Company:		
Genetic Test Results:		

6 PHARMACY PRESCRIPTION

Drug: DAYBUE™ (trofinetide) 200 mg/mL, Oral Solution Prescribing Directions: TakemL Twice Daily Day Supply: Refills:			
Patient's Weight (kg): Administration: 🗆 Oral 🛛 Gastrostomy Tube 🛛 Type: 🗆 NeoMed® Oral Dispenser 🗆 ENFit® 🕁 Luer Lock Syringe			
Additional Prescribing Directions:			
Patient's Allergies: 🗆 NKDA 🛛 Please List:			
Current Medications:			
In their monthly shipments, all patients will receive ancillary materials required for the treatment method selected by the prescriber.			

7 PRESCRIBER AUTHORIZATION

I attest that I have obtained written permission, in the event it is required under applicable federal and/or state law, of my patient (or the patient's legal representative) for the release of my patient's Protected Health Information ("PHI") to Acadia Pharmaceuticals Inc. or its representatives or agents (collectively "Acadia") as may be necessary for the patient's participation in a program designed to assist patients in determining their insurance coverage for DAYBUE that I have elected to prescribe. I direct Acadia to convey, on my behalf, any prescription-related PHI and other prescribing information delivered to Acadia for DAYBUE to the dispensing pharmacy chosen by or for the patient, to the patient's health insurance company, and to other third parties as may be necessary for dispensing the patient's prescription for DAYBUE, with verifying the patient's insurance coverage for DAYBUE, providing information regarding payer coverage and benefits and how to prepare prior authorization requests, coverage determination appeals, or other coverage issues, and/or assisting with patient assistance and support or reduced-cost DAYBUE. I understand I am to comply with the state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. I agree that Acadia may contact me for additional information relating to DAYBUE, including but not limited to via email, fax, and telephone. I appoint Acadia as my agent for the purpose of conveying this prescription to the appropriate dispensing pharmacy. I certify that DAYBUE is medically necessary and in the best interest of the named patient.

My signature below certifies that I have read, understand, and agree to the Prescriber Authorization statement above.

Sign Here	Signature (Dispense as Written):	No Stamp Signature	_ Date:
Sign Here	Signature (Substitution Allowed):	No Stamp Signature	_ Date:
Print Name: _			





Patient's Name:

Date of Birth (MM/DD/YYYY): _

PATIENT/PARENT/LEGAL GUARDIAN HIPAA AUTHORIZATION (Please read and sign below if you agree.)

I hereby authorize and direct my healthcare providers (including physicians, prescribers, providers of long-term care, and pharmacies) and health insurance companies, and each of their respective representatives, employees, staff, and agents (collectively "Providers") to use my Protected Health Information ("PHI") and/or disclose it to Acadia Pharmaceuticals Inc. and its representatives and agents (collectively "Acadia") to assist with my obtaining DAYBUE and Acadia Connect support services. I understand that this PHI may include, but is not limited to, my name, address, phone number, and other contact information; information relating to my medical condition, treatment, care management, and health insurance; as well as information provided on this Form and any prescription. I agree to be enrolled in the Acadia Copay Card Program if eligible, and if I am confirmed eligible, I understand that Copay Card information will be sent to my specialty pharmacy, along with my prescription. I understand any assistance with my cost-sharing or co-payment for DAYBUE will be made in accordance with the Program Terms and Conditions. I understand that pharmacies may receive remuneration (payment) from Acadia for providing patient support services and disclosing associated PHI to Acadia pursuant to this Form.

I further authorize Acadia to use my PHI and disclose it to third parties, including, but not limited to, specialty pharmacies, health plans, insurance companies, and patient assistance programs solely in relation to my obtaining DAYBUE and/or Acadia Connect product support services, including investigating insurance benefits, eligibility, and coverage; providing financial assistance for copay or out-of-pocket payments; eligibility for free medication supply; coordinating care; coordinating the delivery of medication.

I authorize Acadia and Providers to communicate with me via phone, text, or email, using the contact information I have provided on this form, for all of the purposes mentioned above. I confirm that I am the subscriber for the mobile telephone number(s) provided, and I agree to notify Acadia Connect promptly if any of my numbers change in the future. I understand that my wireless service provider's message and data rates may apply. I understand that I can opt out of future text messages by responding STOP to any text. I also understand that additional text messaging terms and conditions may be provided to me in the future as part of an opt-in confirmation text message.

I also authorize Acadia to disclose to my DAYBUE Providers any PHI about me that Acadia may create or receive. I understand that once my PHI is disclosed to or by Acadia pursuant to this Form, it may no longer be protected by state and federal privacy laws and may be subject to re-disclosure. I understand that I may refuse to sign this Form, and my refusal will not affect the treatment I receive from my Providers, nor will it affect my enrollment or eligibility for health insurance benefits to which I am otherwise entitled. I also understand that I may cancel (revoke) this authorization at any time by mailing a letter requesting such cancellation to the address below; however, this cancellation will not apply to any PHI already used or disclosed in reliance on this Form before notice of the cancellation is received by my Providers. I understand that this authorization is valid for a period of 10 years or for a shorter period dictated by applicable state law. I understand that I will be provided with a signed copy of this authorization by the Provider who collects it from me.

Further information concerning Acadia's privacy practices can be found at www.acadia.com/privacy. If you are a resident of California, a description of the personal information collected by Acadia and your rights under the California Consumer Privacy Act can be found at this address. Address to opt out of communications or to cancel this form: Acadia Connect, 1710 Shelby Oaks Dr. Ste 3, Memphis, TN 38134.

I further authorize Acadia Pharmaceuticals Inc. to discuss the coordination of the patient's care with the following family member(s) and/or caregiver(s). These individual(s) have my full permission, on behalf of the patient, to obtain and disclose personal and medical information about the patient, Acadia, and its agents and contractors.

Authorized Representative(s) (please print):			
Name:	Relationship to Patient:		
Name:	Relationship to Patient:		
Sign Here Patient/Parent/Legal Guardian:	Date:		

Please submit completed enrollment form via fax to 1-888-385-2748 or email to DAYBUE@AcadiaConnect.com

©2023 Acadia Pharmaceuticals Inc. Acadia and Acadia Connect are registered trademarks and DAYBUE is a trademark of Acadia Pharmaceuticals Inc. All rights reserved. ACAC-0171 3/23.

